{"id":2820,"date":"2026-06-23T17:42:12","date_gmt":"2026-06-23T17:42:12","guid":{"rendered":"https:\/\/magazines.uthscsa.edu\/cancer-center\/?p=2820"},"modified":"2026-06-23T17:42:12","modified_gmt":"2026-06-23T17:42:12","slug":"drug-found-to-double-survival-time-for-glioblastoma-patients","status":"publish","type":"post","link":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/","title":{"rendered":"Drug found to double survival time for glioblastoma patients"},"content":{"rendered":"

By Steven Lee<\/p>\n

A drug developed at The University of Texas at San Antonio has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults.<\/p>\n

Results of a trial led by the university revealed that a unique investigational drug formulation called Rhenium Obisbemeda (186RNL) more than doubled median survival and progression-free time, compared with standard median survival and progression rates, and with no dose-limiting toxic effects.<\/p>\n

\u201cAs a disease with a pattern of recurrence, resistance to chemotherapies and difficulty to treat, glioblastoma has needed durable treatments that can directly target the tumor while sparing healthy tissue,\u201d said Andrew J. Brenner, MD, PhD, professor and chair of neuro-oncology research with Mays Cancer Center. \u201cThis trial provides hope, with a second phase under way and planned for completion by the end of this year.\u201d<\/p>\n

Brenner, who also is clinical investigator for the Institute for Drug Development at UT San Antonio and co-leader of its Experimental and Development Therapeutics Program, is lead author of the trial\u2019s study, titled, \u201cConvection Enhanced Delivery of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: a multicenter, single arm, phase 1 clinical trial.\u201d It published in the journal Nature Communications.<\/p>\n

Other authors also are with Mays Cancer Center, as well as UT Southwestern Medical Center of Dallas, Case Western Reserve University, University of Texas MD Anderson Cancer Center and trial sponsor Plus Therapeutics Inc., a clinical-stage pharmaceutical company receiving license to the trial technology to investigate the treatment of central nervous system cancers.<\/p>\n

Brenner said that the median overall survival time for patients with glioblastoma after standard treatment fails with surgery, radiation and chemotherapy is only about eight months. More than 90% of patients have a recurrence of the disease at its original location.<\/p>\n

Rhenium Obisbemeda enables very high levels of a specific activity of rhenium-186 (186Re), a beta-emitting radioisotope, to be delivered by tiny liposomes, referring to artificial vesicles or sacs having at least one lipid bilayer. The researchers used a custom molecule known as BMEDA to chelate or attach 186Re and transport it into the interior of a liposome where it is irreversibly trapped.<\/p>\n

In this trial, known as the phase 1 ReSPECT-GBM trial, scientists set out to determine the maximum tolerated dose of the drug, as well as safety, overall response rate, disease progression-free survival and overall survival.<\/p>\n

After failing one to three therapies, 21 patients who were enrolled in the study between March 5, 2015, and April 22, 2021, were treated with the drug administered directly to the tumors using neuronavigation and convection catheters.<\/p>\n

The researchers observed a significant improvement in survival compared with historical controls, especially in patients with the highest absorbed doses, with a median survival and progression-free time of 17 months and six months, respectively, for doses greater than 100 gray (Gy), referring to units of radiation.<\/p>\n

Importantly, they did not observe any dose-limiting toxic effects, with most adverse effects deemed unrelated to the study treatment.<\/p>\n

\u201cThe combination of a novel nanoliposome radiotherapeutic delivered by convection-enhanced delivery, facilitated by neuronavigational tools, catheter design and imaging solutions, can successfully and safely provide high absorbed radiation doses to tumors with minimal toxicity and potential survival benefit,\u201d Brenner concluded.<\/p>\n

\n
\"Sandeep
Sandeep Burma, PhD, professor and vice chair (research) of neurosurgery with Mays Cancer Center.<\/figcaption><\/figure>\n

Researchers discover way to slow or block recurrence of glioblastoma\u00a0<\/strong><\/span><\/h2>\n

By Steven Lee<\/p>\n

Researchers at The University of Texas at San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation, bringing new hope
\nfor survival.<\/p>\n

Ironically, the scientists found that the customary treatment for glioblastoma, ionizing radiation, can also cause tumors to recur, by generating senescent or aged cells that secrete molecules that can spur growth of neighboring cancer cells.<\/p>\n

But they discovered that a new class of experimental \u201csenolytic\u201d drugs, given after radiation, can kill those senescent cells while sparing normal ones, thereby stemming recurrence. A senolytic refers to a novel class of small molecules thought to selectively induce death of senescent cells.<\/p>\n

\u201cThese findings lend credence to the \u2018one-two punch\u2019 approach to radiation therapy, where radiation or other agents are first used to induce senescence in a tumor, and then the senescent cells are removed by a senolytic,\u201d said Sandeep Burma, PhD, professor and vice chair (research) of neurosurgery at UT San Antonio and Mays Cancer Center.<\/p>\n

Burma and Bipasha Mukherjee, PhD, associate professor of neurosurgery at UT San Antonio, are lead authors of the study, \u201cTargeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy,\u201d published Feb. 19 in the journal EMBO Molecular Medicine. Other authors also are with the departments of neurology, biochemistry and structural biology, and medicine at UT San Antonio, as well as the University of Texas Southwestern Medical Center in Dallas, and the Mayo Clinic of Rochester, Minnesota.<\/p>\n

A double-edged sword<\/span><\/strong><\/h3>\n

Recurrence of glioblastoma, the most common primary brain tumor in adults, is a major clinical problem as it occurs quickly and can be even more aggressive. Accordingly, Burma\u2019s lab has focused on understanding the forces driving recurrence and strategies to block the process.<\/p>\n

Specifically, they are trying to understand whether senescence of cancer cells after radiation therapy \u2013 also called therapy-induced senescence, or TIS \u2013 might counterintuitively be driving recurrence.<\/p>\n

Burma said that ionizing radiation, which is routinely and, in many cases, effectively used to treat cancer, is a double-edged sword since radiation also is a powerful carcinogen. For glioblastoma, radiation is still the most effective therapy. But radiation exposure also is the only known risk factor for its development, and could perhaps also drive recurrence.<\/p>\n

When a tumor is radiated, a cancer cell can either die or remain alive but be permanently unable to divide further, a state called senescence, with both outcomes controlling tumor growth.<\/p>\n

However, researchers in this study discovered that senescent glioblastoma cells secrete large amounts of growth factors and other molecules that can act on persisting cancer cells and encourage them to re-proliferate. What could be done about this problem?<\/p>\n

End of senescence<\/strong><\/span><\/h3>\n

Senolytic gets its name from the words \u201csenescence\u201d and \u201clytic,\u201d or destroying.<\/p>\n

The researchers found that senescent glioblastoma cells rely on an anti-apoptotic protein, or one that slows or prevents cell death known as cIAP2, for survival. They also found that targeting cIAP2 with a senolytic drug called birinapant in mouse tumor models after radiation could kill senescent cells while sparing normal cells.<\/p>\n

They tested their approach in multiple mouse models of glioblastoma and found that while the drug was not effective on its own, it was very effective at delaying or even preventing recurrence if given as an \u201cadjuvant\u201d after radiotherapy.<\/p>\n

\u201cThese pre-clinical results highlighting a novel senolytic approach for glioblastoma are very exciting from a clinical standpoint as they clearly indicate that significant improvement in patient survival may become possible by eliminating senescent cells arising after radiotherapy,\u201d Burma concluded.<\/p>\n","protected":false},"excerpt":{"rendered":"

By Steven Lee A drug developed at The University of Texas at San Antonio has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that a unique investigational drug formulation called Rhenium Obisbemeda (186RNL) more than doubled median […]<\/p>\n","protected":false},"author":653,"featured_media":2821,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"magazine":[22],"issue-year":[79],"featured-story":[36],"class_list":["post-2820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","magazine-cancer-center","issue-year-79","featured-story-homepage"],"yoast_head":"\nDrug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report\" \/>\n<meta property=\"og:description\" content=\"By Steven Lee A drug developed at The University of Texas at San Antonio has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that a unique investigational drug formulation called Rhenium Obisbemeda (186RNL) more than doubled median […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Mays Cancer Center Annual Report\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T17:42:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-850x476.png\" \/>\n\t<meta property=\"og:image:width\" content=\"850\" \/>\n\t<meta property=\"og:image:height\" content=\"476\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"dominguezp2\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"dominguezp2\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/\"},\"author\":{\"name\":\"dominguezp2\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/c734dd974c7c296a670851e101671c32\"},\"headline\":\"Drug found to double survival time for glioblastoma patients\",\"datePublished\":\"2026-06-23T17:42:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/\"},\"wordCount\":1148,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2026\\\/06\\\/04_glioblastoma-scaled.png\",\"articleSection\":[\"Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/\",\"name\":\"Drug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2026\\\/06\\\/04_glioblastoma-scaled.png\",\"datePublished\":\"2026-06-23T17:42:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/c734dd974c7c296a670851e101671c32\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2026\\\/06\\\/04_glioblastoma-scaled.png\",\"contentUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/2026\\\/06\\\/04_glioblastoma-scaled.png\",\"width\":2560,\"height\":1433,\"caption\":\"Andrew J. Brenner, MD, PhD, professor and chair of neuro-oncology research with Mays Cancer Center.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/2026\\\/06\\\/23\\\/drug-found-to-double-survival-time-for-glioblastoma-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mays Cancer Center Annual Report\",\"item\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/magazine\\\/cancer-center\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Drug found to double survival time for glioblastoma patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#website\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/\",\"name\":\"Mays Cancer Center Annual Report\",\"description\":\"Mays Cancer Center Annual Reports\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/#\\\/schema\\\/person\\\/c734dd974c7c296a670851e101671c32\",\"name\":\"dominguezp2\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g\",\"caption\":\"dominguezp2\"},\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/cancer-center\\\/author\\\/dominguezp2\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/","og_locale":"en_US","og_type":"article","og_title":"Drug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report","og_description":"By Steven Lee A drug developed at The University of Texas at San Antonio has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that a unique investigational drug formulation called Rhenium Obisbemeda (186RNL) more than doubled median […]","og_url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/","og_site_name":"Mays Cancer Center Annual Report","article_published_time":"2026-06-23T17:42:12+00:00","og_image":[{"width":850,"height":476,"url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-850x476.png","type":"image\/png"}],"author":"dominguezp2","twitter_card":"summary_large_image","twitter_misc":{"Written by":"dominguezp2","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#article","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/"},"author":{"name":"dominguezp2","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/c734dd974c7c296a670851e101671c32"},"headline":"Drug found to double survival time for glioblastoma patients","datePublished":"2026-06-23T17:42:12+00:00","mainEntityOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/"},"wordCount":1148,"commentCount":0,"image":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-scaled.png","articleSection":["Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/","name":"Drug found to double survival time for glioblastoma patients - Mays Cancer Center Annual Report","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#website"},"primaryImageOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#primaryimage"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-scaled.png","datePublished":"2026-06-23T17:42:12+00:00","author":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/c734dd974c7c296a670851e101671c32"},"breadcrumb":{"@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#primaryimage","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-scaled.png","contentUrl":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-content\/uploads\/sites\/12\/2026\/06\/04_glioblastoma-scaled.png","width":2560,"height":1433,"caption":"Andrew J. Brenner, MD, PhD, professor and chair of neuro-oncology research with Mays Cancer Center."},{"@type":"BreadcrumbList","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/2026\/06\/23\/drug-found-to-double-survival-time-for-glioblastoma-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/magazines.uthscsa.edu\/cancer-center\/"},{"@type":"ListItem","position":2,"name":"Mays Cancer Center Annual Report","item":"https:\/\/magazines.uthscsa.edu\/cancer-center\/magazine\/cancer-center\/"},{"@type":"ListItem","position":3,"name":"Drug found to double survival time for glioblastoma patients"}]},{"@type":"WebSite","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#website","url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/","name":"Mays Cancer Center Annual Report","description":"Mays Cancer Center Annual Reports","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/magazines.uthscsa.edu\/cancer-center\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/magazines.uthscsa.edu\/cancer-center\/#\/schema\/person\/c734dd974c7c296a670851e101671c32","name":"dominguezp2","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/54820ebd1a094dbfe7013ab038b785a715c44b8cea595ffa16259759c8dbeb19?s=96&d=mm&r=g","caption":"dominguezp2"},"url":"https:\/\/magazines.uthscsa.edu\/cancer-center\/author\/dominguezp2\/"}]}},"_links":{"self":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts\/2820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/users\/653"}],"replies":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/comments?post=2820"}],"version-history":[{"count":5,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts\/2820\/revisions"}],"predecessor-version":[{"id":2835,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/posts\/2820\/revisions\/2835"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/media\/2821"}],"wp:attachment":[{"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/media?parent=2820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/categories?post=2820"},{"taxonomy":"magazine","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/magazine?post=2820"},{"taxonomy":"issue-year","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/issue-year?post=2820"},{"taxonomy":"featured-story","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/cancer-center\/wp-json\/wp\/v2\/featured-story?post=2820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}